Off Label NCCN denied as not FDA-approved for this use by Aetna?
Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Aetna typically requires
Aetna's specific coverage criteria for off label nccn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Aetna angle on Off Label NCCN
## Why Aetna Denied an Off-Label NCCN-Supported Treatment as Not FDA-Approved — and How to Appeal
"Not FDA-approved" denials for NCCN-supported treatments are among the most misunderstood in oncology coverage. The denial does not necessarily mean the drug lacks FDA approval — it often means the drug is FDA-approved for a different indication and is being used off-label for your specific diagnosis. Off-label use of FDA-approved drugs is standard medical practice in oncology, and federal law — as well as Aetna's own policies — recognize this. Aetna's Clinical Policy Bulletins generally state that off-label use may be covered when supported by recognized drug compendia, including the NCCN Compendium.
### Why This Denial Is Appealable
If the drug has FDA approval for any indication, and the NCCN Compendium lists your specific off-label use, Aetna's "not FDA-approved" denial is internally inconsistent with its own coverage policy. This is one of the strongest grounds for appeal, and IROs reviewing these denials under ACA §2719 and ERISA §503 frequently reverse them when compendium support is clearly documented. The key is showing that the drug is FDA-approved (for something) and that the off-label use is NCCN-supported.
### Federal Appeal Framework
- Internal appeal: File within 180 days. Aetna must respond within 30–60 days for standard reviews or 72 hours for urgent/expedited requests.
- External review: If the internal appeal is denied, you have approximately four months to file. An Independent Review Organization issues a binding decision.
- Expedited option: Request this in writing if delay endangers your health — applicable at both internal and external stages.
### Documentation to Gather
1. FDA approval documentation — print the FDA drug label from the FDA website (Drugs@FDA) showing the drug's approved status. This establishes the drug is not experimental or unapproved — it is approved for a different indication. 2. Off-label indication documentation — records establishing your diagnosis, histology, staging, and any molecular or biomarker findings that define the NCCN-listed off-label indication. 3. NCCN Compendium entry — the specific entry showing the drug listed for your off-label indication with its NCCN evidence category. Your oncologist can obtain this directly from NCCN. 4. Aetna Clinical Policy Bulletin — request the specific CPB Aetna used. Identify the section acknowledging compendia-supported off-label coverage and quote it in your appeal. 5. Prescriber letter — your oncologist should clearly state: (a) the drug is FDA-approved (identifying the approved indication), (b) it is being used off-label for your diagnosis, and (c) that off-label use is supported by the NCCN Compendium at a specified category.
### Criteria-Mapping Structure
| Issue Raised in Denial | Specific Rebuttal and Documentation | |---|---| | Drug not FDA-approved | [FDA label from Drugs@FDA — drug IS approved for X indication] | | Use not approved for this indication | [Acknowledged — this is off-label use] | | Off-label use not covered | [Aetna CPB section acknowledging compendia coverage] | | NCCN support for this indication | [NCCN category, compendium edition, date] |
Frame the appeal to distinguish between "not FDA-approved at all" (which would be a different situation) and "FDA-approved drug used off-label with compendia support" — Aetna's own policy covers the latter.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →